Wisevoter
World

ETS1 Knockdown Shields Kidneys From Injury

Rat and cell-model research links the transcription factor ETS1 to PARP1 expression and kidney damage after blood flow is restored.

Updated on Nov. 7, 2026 in Stroke

Bold flat-color vector illustration of a kidney split into a smooth coral half and a fractured teal half, with a mustard gene strand feeding a cream protein block.
Researchers found that suppressing the transcription factor ETS1 shielded rat kidneys from injury after blood flow was interrupted and restored, pointing to PARP1 as a possible target. AI Illustration. Upload story photo >

Researchers report that knocking down the transcription factor ETS1 protected kidneys from ischemia-reperfusion injury by inhibiting PARP1 transcription. PARP1 inhibitors Veliparib and PJ34 likewise reduced kidney damage and improved renal function in rats.

Why it matters

Kidney injury from interrupted and then restored blood flow is a common complication in surgery and transplantation, and the study identifies a specific regulatory pathway that could be targeted. The findings are preclinical and do not yet establish a treatment for patients.

The study used a clamped renal artery rat model and oxygen-glucose deprivation/reoxygenation-treated HK2 cells, with Veliparib and PJ34 improving renal function in the rat model. Human clinical efficacy and safety remain untested.

The details

Renal ischemia-reperfusion injury was induced in rats by clamping the renal artery, while human renal tubular HK2 cells were exposed to oxygen-glucose deprivation followed by reoxygenation. The researchers found that ETS1 acts as a transcription factor that regulates the PARP1 promoter, and that knocking it down reduced apoptosis, DNA damage and inflammatory cytokines.

Timeline

  1. November 7, 2026: Article published as accepted early-access research.

Health Landscape

The work extends the line of PARP inhibitor research that has examined the enzyme PARP1 in tissue injury, adding ETS1 as an upstream regulator. It remains at the laboratory and animal stage within that broader research effort.

For patients, this research does not yet change treatment options or daily health routines. Any future therapy based on these pathways would require human clinical trials before becoming available.

The takeaway

Kidney protection after blood flow restoration may depend on the ETS1–PARP1 pathway, a lead that now requires testing beyond rodent and cell models before any clinical implication can be drawn.

Further reading

Explore more on Stroke research and related vascular injury topics.

Source note: This article includes information reported by Nature.